



Summary of CEPI JCG Meeting

Teleconference, 30 April 2020

Chair

- Peggy Hamburg

Invited *(alphabetical by first name)*

- | | |
|----------------------------|-----------------------|
| • Ana Maria Henao Restrepo | • Richard Hatchett |
| • Aurelia Nguyen | • Rihana Diabo |
| • Charlie Weller | • Robin Nandy |
| • Daniel Brasseur | • Shannon Quinlan |
| • David John Wood | • Sophie Mathewson |
| • Dawn OConnell | • Svein Rune Andersen |
| • Debra Yeskey | • Wilson Mok |
| • Deusdedit Mubangizi | |
| • Diadié Maiga | |
| • Elen Høeg | |
| • Els Torreele | |
| • Emanuele Capobianco | |
| • Emer Cooke | |
| • Frederik Kristensen | |
| • Haja Bally | |
| • hrees | |
| • Jakob Cramer | |
| • Jodie Rogers | |
| • Joseph Simmonds-Issler | |
| • Luc Debruyne | |
| • Marco Cavaleri | |
| • Marion Gruber | |
| • Mark Feinberg | |
| • Mark Page | |
| • Melanie Saville | |
| • Murray Lumpkin | |
| • Nicole Lurie | |
| • Paul Kristiansen | |

Summary

The JCG met to discuss the recent announcement of the Access to Covid Tools (ACT) Accelerator initiative and the subsequent impact the announcement might have on the JCG's work ahead. The meeting was informational, rather than decisional.

Peggy Hamburg, the chair, opened the meeting and offered participants the opportunity to share relevant updates. **Daniel Brasseur**, the chair of the Regulatory Working Group, shared that while regulators remain ready to work with urgency on COVID related products, it seems they are more likely to work with individual manufacturers on a case-by-case basis rather deciding on general parameters for all the products to achieve. **Ana Maria Henao Restrepo**, with the WHO's R&D Blueprint team, shared updates from the WHO team on preclinical work, animal models, the TPP finalization process, and clinical trial protocol development.

Frederik Kristensen, Deputy CEO of CEPI, and **Richard Hatchett**, CEO of CEPI, shared an overview of the ACT Accelerator (global public-private initiative to accelerate the development of COVID vaccines, therapeutics, and diagnostics) and how the Vaccine Pillar within the ACT Accelerator might be organized (co-led by CEPI and Gavi).

The JCG was given the opportunity to comment, ask questions, and reflect on the potential implications of the new initiative on the work ahead for the JCG. The comments touched on these themes:

- (1) Multiple JCG members are heavily involved in the ACT Accelerator. The JCG does not want to duplicate the work being undertaken there.
- (2) The JCG continues to have an end-to-end view of development and deployment and will be available for consultation on Vaccine Pillar issues
- (3) The JCG will continue to focus on CEPI's other vaccines as well.
- (4) The JCG might consider exploring and strategizing on what the landscape will look like post-COVID.

While the Vaccine Pillar is still under construction, and some of the issues around organization and subsequent implications for the JCG are still unknowable, the JCG agreed to stay in touch and continue to think through what its next steps and path forward in the light of ACT Accelerator might be.

Peggy concluded the meeting with a promise to stay in touch and continue to think through the implications. The JCG will meet again in a few weeks.